Rapt Therapeutics Inc Net Income per Employee (RAPT), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Rapt Therapeutics Inc   (NASDAQ: RAPT)
 

Rapt Therapeutics Inc Net Income per Employee

RAPT's Quarterly Results, Trends, Rankings, Statistics
Rapt Therapeutics Inc recorded a cumulative net loss of $-106 million during 12 month ending in the third quarter 2025.
The Healthcare sector has seen employees of 380 other companies achieving higher income per employee. While Rapt Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 3478 to 4030.


What is Income per Employee Ratio?






RAPT Net Income per Employee (Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
(Mar 31 2025)
I. Quarter
(Dec 31 2024)
IV. Quarter
(Sep 30 2024)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -2,515,167 -2,535,452 -2,774,024 -3,092,024 -2,559,333
RAPT's Total Ranking # 4030 # 3478 # 1664 # 2975 # 2713
Seq. Net Income Change - - - - -


RAPT Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 381
Healthcare Sector # 827
Overall Market # 4030

Net Income per Employee Statistics
High Average Low
$ -237,405 $ -1,968,540 $ -3,092,024
(Sep 30 2019)   (Dec 31 2024)







Companies with similar Income per Employee for 12 month ending Sep 30 2025, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2025Number of Employees Sep 30 2025


Date modified: 2026-08-29T17:41:26+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.